Cora Sternberg

@cnsternberg

Physician-Scientist. Professor of Medicine, Medical Oncologist . Clinical Director, Englander Institute for Precision Medicine.

Vrijeme pridruživanja: travanj 2009.

Tweetovi

Blokirali ste korisnika/cu @cnsternberg

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @cnsternberg

  1. 30. sij

    Congratulations to all for this important endeavor!

    Poništi
  2. 30. sij
    Poništi
  3. 25. sij

    Precion delivery of cancer care is the next step!

    Poništi
  4. proslijedio/la je Tweet
    25. sij

    How cool is this?! 😎😎😎Deterministic Barcoding in Tissue for spatial omics sequencing (DBiT-seq). mRNA, Protein and more barcoded using parallel microfluidic channels on FFPE enabling the construction of a high-spatial-resolution multi-omics atlas by NGS sequencing.

    Poništi
  5. proslijedio/la je Tweet
    15. sij

    Addresses important ?’s. Don’t give higher dose or more than 6 cycles as single agent. Still wonder about retreatment

    Poništi
  6. proslijedio/la je Tweet
    13. sij

    Announcing the new issue of our ! Issue 5:4 has the very latest review and research articles Read all content at

    Poništi
  7. 6. sij
    Poništi
  8. proslijedio/la je Tweet
    27. pro 2019.

    Recommended reading for break: How I Treat Side Effects of Immunotherapy Special Issue ESMO - European Society for Medical Oncology The Daily Tweet

    Poništi
  9. proslijedio/la je Tweet
    22. pro 2019.

    Continuing the momentum with patient advocacy and discuss the importance of patient advocacy, education, and the impact advocacy has on a cancer patients' journey on UroToday >

    Poništi
  10. proslijedio/la je Tweet
    22. pro 2019.
    Poništi
  11. proslijedio/la je Tweet
    22. pro 2019.

    There’s No Winter Break From ‘Publish or Perish’ via ⁦⁩ -new data showing a substantial proportion of manuscript submissions & journal reviews done over the holidays 😞

    Poništi
  12. proslijedio/la je Tweet
    18. pro 2019.

    Huge news for with new agent (EV) approved! More to come! Good to look ORR & outcomes with EV in pts with FGFR alterations! Field moving forward

    Poništi
  13. proslijedio/la je Tweet
    18. pro 2019.

    I am proud to say that Enfortumab vedotin was approved by the FDA today for advanced bladder cancer. A heartfelt thanks to all the patients and families who volunteered for the clinical trials. And a special thanks to our research staff and nurses who worked tirelessly.

    Poništi
  14. proslijedio/la je Tweet
    18. pro 2019.

    Enfortumab Vedotin is clearly very active in bladder cancer with over 40% RR in refractory disease. The randomised 301 trial will determine the degree of benifit. Also, EV with pembro could replace front line chemo in view of the >70% RR. Patient will want this too I suspect.

    Poništi
  15. proslijedio/la je Tweet
    17. pro 2019.

    Congrats Betsy on your election to Board of Directors !! Richly deserved!

    Poništi
  16. 19. pro 2019.
    Poništi
  17. proslijedio/la je Tweet
    16. pro 2019.
    Poništi
  18. proslijedio/la je Tweet

    Great interview with Clinical Director Cora N. Sternberg, M.D. ().

    Poništi
  19. proslijedio/la je Tweet
    3. pro 2019.

    “This trial, absolutely, is paradigm-changing,” tells . Watch as she discusses the CARD study of cabazitaxel vs abiraterone or enzalutamide in metastatic .

    Poništi
  20. 11. pro 2019.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·